Not for human consumption, therapeutic, veterinary, cosmetic, or diagnostic use
Figure 1: Changes in body weight from baseline to the end of treatment at week 26 associated with the trial product estimand, in the randomly assigned treatment groups administered either 0.3 mg of cagrilintide, 0.6 mg of cagrilintide, 1.2 mg of cagrilintide, 2.5 mg of cagrilintide, 4.5 mg of cagrilintide, 3.0 mg of liraglutide, or a placebo
Western blot Cells were harvested and proteins were extracted using cell lysis buffer supplemented with 0.3% phenylmethylsulfonyl fluoride and proteinase and phosphatase inhibitors
I.LinkW
These injections last just under a week, so it is recommended to receive the injections twice a week, and include a Vitamin B12 shot for maximum benefit